Depiction of Prostate Cancer Treatment Alternatives in Greece
NCT ID: NCT00733213
Last Updated: 2009-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
310 participants
OBSERVATIONAL
2008-01-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Target Group: Patients with locally advanced or metastatic prostate cancer.
* The first 10 consecutive patients records that meet the entry criteria.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Label Prostate Cancer Study in Japanese Patients
NCT01351688
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00219271
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
NCT07146113
Genetic Studies of Prostate Cancer Aggressiveness and Prognosis
NCT06773858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients that received Hormonal therapy.
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca, SA Greece
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Panagiotis Pontikis, MD
Role: STUDY_DIRECTOR
AstraZeneca Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Athens, , Greece
Research Site
Karditsa, , Greece
Research Site
Serres, , Greece
Research Site
Xsanthi, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OGR-DUM-2007/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.